New Zealand's parliament passed the Misuse of Drugs (Medicinal Cannabis) Amendment Act in December of 2018, removing CBD from the country's list of controlled drugs, defining it instead as a prescription medicine. To access any CBD product, a consumer must go through the same steps and requirements as they would to access any other pharmaceutical medicine – a doctor's visit, a prescription, and a pharmacy are necessary before a patient can access CBD.
New Zealand's allowed limit on THC as a contaminant in CBD products is higher than most countries' – THC must not exceed 2.0% of the total content.
The country has relatively high cultural acceptance of cannabis usage and will vote in a popular referendum to legalize adult-use cannabis in September 2020. The question will be included as part of the country's General Election and will be posed in a straightforward question, “Do you support the proposed Cannabis Legalization and Control Bill?” Because the country identifies no difference between cannabis products with CBD and cannabis products with THC in them, this bill will have huge ramifications for the CBD industry as well. The main regulations up for consideration include a limit of home-growing to two plants per adult, a possession limit of 14 grams of dried cannabis, a minimum age of 20 years to possess, protection for 'consumption premises' which could include food and beverage sales, and stringent regulations which effectively ban all advertisements.
The passing of the adult-use bill would be great news for consumers, who would have access to much more affordable products, but would spell great competition for burgeoning cannabis producers in the country.